Integra LifeSciences (NASDAQ:IART) Lowered to “Sell” at Citigroup

Citigroup lowered shares of Integra LifeSciences (NASDAQ:IART) from a neutral rating to a sell rating in a research note released on Tuesday, Marketbeat.com reports. They currently have $23.00 price target on the life sciences company’s stock, down from their prior price target of $30.00.

IART has been the topic of a number of other research reports. JMP Securities cut their target price on Integra LifeSciences from $49.00 to $40.00 and set a market outperform rating on the stock in a research report on Tuesday, May 7th. Wells Fargo & Company cut Integra LifeSciences from an overweight rating to an equal weight rating and dropped their price target for the company from $45.00 to $25.00 in a research report on Tuesday, May 7th. Oppenheimer cut Integra LifeSciences from an outperform rating to a market perform rating in a research report on Tuesday, May 7th. Morgan Stanley boosted their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an underweight rating in a research report on Monday, July 15th. Finally, Truist Financial boosted their price target on Integra LifeSciences from $25.00 to $32.00 and gave the company a hold rating in a research report on Tuesday, July 16th. Four analysts have rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences presently has an average rating of Hold and an average price target of $29.25.

Integra LifeSciences Stock Down 2.3 %

IART opened at $24.04 on Tuesday. The business’s 50-day simple moving average is $29.44 and its 200-day simple moving average is $33.27. The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 3.39. Integra LifeSciences has a one year low of $22.36 and a one year high of $45.65. The stock has a market capitalization of $1.87 billion, a P/E ratio of 48.08, a price-to-earnings-growth ratio of 0.84 and a beta of 1.11.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. The business had revenue of $418.20 million for the quarter, compared to analysts’ expectations of $413.07 million. During the same quarter in the previous year, the firm earned $0.71 earnings per share. The business’s revenue was up 9.7% compared to the same quarter last year. Analysts anticipate that Integra LifeSciences will post 2.47 EPS for the current year.

Insider Buying and Selling at Integra LifeSciences

In other Integra LifeSciences news, Chairman Stuart Essig acquired 52,641 shares of the stock in a transaction on Thursday, May 23rd. The shares were bought at an average price of $28.49 per share, with a total value of $1,499,742.09. Following the acquisition, the chairman now owns 487,922 shares of the company’s stock, valued at $13,900,897.78. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently modified their holdings of the company. Capital Research Global Investors boosted its stake in shares of Integra LifeSciences by 37.7% during the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock worth $209,828,000 after acquiring an additional 1,621,655 shares in the last quarter. Madison Avenue Partners LP boosted its stake in shares of Integra LifeSciences by 8.0% during the 4th quarter. Madison Avenue Partners LP now owns 1,042,156 shares of the life sciences company’s stock worth $45,386,000 after acquiring an additional 77,489 shares in the last quarter. Leeward Investments LLC MA boosted its stake in shares of Integra LifeSciences by 17.8% during the 1st quarter. Leeward Investments LLC MA now owns 452,438 shares of the life sciences company’s stock worth $16,039,000 after acquiring an additional 68,247 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Integra LifeSciences by 4.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,615,112 shares of the life sciences company’s stock worth $70,340,000 after acquiring an additional 63,323 shares in the last quarter. Finally, Cooke & Bieler LP boosted its stake in shares of Integra LifeSciences by 4.4% during the 4th quarter. Cooke & Bieler LP now owns 2,834,604 shares of the life sciences company’s stock worth $123,447,000 after acquiring an additional 120,410 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.